June 2004
Clinical Infectious Diseases;6/1/2004, Vol. 38 Issue 11, p3
Academic Journal
The Pharmaceutical firm Aventis Pasteur Inc. is recalling its rabies vaccine in several countries after live rabies virus was discovered in one batch. The company says that this is a precautionary measure stemming from the discovery through routine testing of a non-inactivated production strain of virus in a single product lot, which was not distributed. Four lots of Imovax vaccine are being withdrawn in the United States, one in Great Britain, and two in Ireland. The lots being recalled passed all release tests, including testing to confirm the absence of live virus.


Related Articles

  • Manufacturer's Recall of Human Rabies Vaccine—April 2, 2004.  // JAMA: Journal of the American Medical Association;5/19/2004, Vol. 291 Issue 19, p2311 

    Presents a follow up on a product recall from the Centers for Disease Control and Prevention. Voluntary recall of human rabies vaccine in April 2004; Reasons for the recall of IMOVAX Rabies Vaccine which is made by Aventis Pasteur; No reported linked illnesses from those who had the vaccine;...

  • WORLDWIDE RABIES VACCINE RECALL.  // Materials Management in Health Care;May2004, Vol. 13 Issue 5, p5 

    Reports on Aventis Pasteur's recall of its Imovax Rabies Vaccine following a quality-assurance test that found a live strain of the rabies virus in another bath of the vaccine produced by the company. Distribution period of tainted products in the United States; Aventis' advice to health care...

  • Aventis cautions against shipping gray Imovax.  // Drug Topics;10/6/2003, Vol. 147 Issue 19, p8 

    Reports that Aventis Pasteur Inc. is asking distributors of its Imovax brand of rabies vaccine in October 2003, to stop shipping the older-style, gray plastic boxes because they may lack a vial for freeze-dried suspension of rabies vaccine.

  • Troubled UK Factory Makes US Feel Fluish. Houlton, Sarah // Pharmaceutical Executive;Nov2004, Vol. 24 Issue 11, p25 

    The article reports that Chiron Corp., the world's second largest manufacturer of flu vaccine, had its manufacturing license withdrawn by the Great Britain Medicines and Healthcare Products Regulatory Agency when a batch of its Fluvirin vaccine became contaminated by bacteria. Chiron is one of...

  • Nurses fear new vaccines muddle.  // Practice Nurse;11/12/2004, Vol. 28 Issue 8, p6 

    Focuses on the similarities in the packaging and brand names of vaccines Repevax and Revaxis. Information on the vaccines; Possible problem posed by the similarities to nurses; Efforts of drug manufacturer Aventis Pasteur to provide nurses with an at-a-glance reminder of the brand names of the...

  • Rx.  // Drug Topics;10/16/2000, Vol. 144 Issue 20, p76 

    Presents information on various drugs released in the United States as of October 16, 2000. Tripedia vaccine from Aventis Pasteur company for diphtheria, tetanus and pertussis immunization series; Atacand HCT from AstraZeneca LP as a second-line treatment for hypertension; Roxicodone from...

  • ANNEX 1: Approved yellow fever vaccine producers.  // International Travel & Health 2005;1/1/2005, p182 

    The article presents a lists of several vaccine manufacturers which have been approved by the World Health Organization to provide yellow fever vaccines around the world. Among the producers include the Aventis Pasteur Inc. in Lyon France, the BioManguinhos in Rio de Janeiro, Brazil, and...

  • Avaxim.  // Royal Society of Medicine: Medicines;2002, p93 

    This article presents information on Avaxim from Aventis Pasteur. It was said that Avaxim is a proprietary, prescription-only preparation of hepatitis A vaccine. It can be used to protect people at risk from infection with hepatitis. Avaxim is available as an injection.

  • Global disease.  // MLO: Medical Laboratory Observer;Dec2004, Vol. 36 Issue 12, p6 

    This article discusses the prevention of global influenza. Amid predictions of a global influenza pandemic within the next five years, the World Health Organization convened a flu vaccine summit in Geneva, Switzerland, on November 11 to encourage development of vaccines against avian influenza...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics